GlassScriptPhysician profile
Li Yee Guo
NPI 1063482552
$5,956.52
in general payments reported to CMS, 2019-2025
27 companies · $3,212 in 2025
The $3,212 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $487 · 2022: $130 · 2023: $549 · 2024: $1,419 · 2025: $3,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,086 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,085.87 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,031.03 | 2019-2025 | Livdelzi |
| Astrazeneca Pharmaceuticals LP | $829.83 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $476.34 | 2020-2025 | |
| Astellas Pharma US INC | $372.50 | 2023-2025 | Veozah |
| Amgen INC. | $355.82 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $337.81 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $293.51 | 2023-2025 | |
| Glaxosmithkline, LLC. | $280.18 | 2023-2025 | Shingrix, Arexvy, Menveo |
| Amarin Pharma, INC. | $240.31 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $216.66 | 2025 | Zenpep |
| Radius Health, INC. | $170.14 | 2020-2025 | Tymlos |
| Novo Nordisk INC | $169.12 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $166.63 | 2024-2025 | Mounjaro, Jardiance, Kisunla |
| Otsuka America Pharmaceutical, INC. | $124.85 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $120.25 | 2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $107.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.52 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $94.73 | 2024-2025 | |
| Exact Sciences Corporation | $90.48 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $68.23 | 2025 | Zoryve |
| Dexcom, INC. | $62.93 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.38 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $45.12 | 2024-2025 | Nexletol |
| Sanofi Pasteur INC. | $44.52 | 2023 | |
| Csl Behring | $43.30 | 2024 | Haegarda |
| Lundbeck LLC | $26.29 | 2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $25.25 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Yee Guo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.